患者团体与制药业之间的「资产交换」互动:澳大利亚定性研究
该研究基于伦理理论对澳大利亚23个患者团体的27名代表进行定性访谈,识别出患者团体与制药业之间的四种关系类型,其中以成功商业伙伴关系为主导。接受资助的团体以金钱、信息和咨询换取为药企提供营销、关键意见领袖关系搭建、协同游说药品准入与补贴、协助临床试验招募及提升企业可信度等「资产」。
要点
- 患者团体与制药业关系以商业伙伴关系为主导,存在「资产交换」。
- 接受资助的团体可能被要求提供营销、游说、招募等具体资产。
- 选择性资助可能使患者团体倡导活动偏向制药业利益。
核心结论
- 患者团体对制药业资助态度多样,接受资助者存在「资产交换」并可能面临被要求提供特定资产的风险。
- 选择性资助可能使患者团体部门活动偏向制药业利益,并允许行业对倡导和后续卫生政策施加代理影响。
研究设计与样本
- 基于伦理理论的实证定性访谈研究,纳入澳大利亚23个患者团体的27名参与者。
- 患者团体在财务参与制药业程度上多样,聚焦一般健康消费者议题或疾病特定主题,辖区为区域或全国。
- 分析采用扎根理论技术,将访谈转录稿编码为数据驱动类别并形成新概念类别。
主要发现
- 识别出四种患者团体与制药业关系类型,主导类型为成功商业伙伴关系。
- 部分参与者描述不满意或未发展的关系,一些一般健康消费者团体认为其使命与制药业根本对立。
- 当公司有成员可能感兴趣的新药时,患者团体与制药公司互动更常见。
- 接受行业资助的患者团体与公司进行「资产」交换:获得金钱、信息和咨询,提供营销、关键意见领袖关系搭建、协同游说药品准入与补贴、协助临床试验招募及提升企业可信度。
临床怎么用
- 患者团体应识别并管理对制药业资助的伦理担忧,接受资助者应预期可能被要求提供特定资产作为回报。
- 理解患者团体对制药业赞助的多种观点有助于团体管理相关伦理问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To understand and report on the nature of patient group interactions with the pharmaceutical industry from the perspective of patient group representatives by exploring the range of attitudes towards pharmaceutical industry sponsorship and how, why, and when interactions occur. DESIGN: Empirical qualitative interview study informed by ethics theory. SETTING: Australian patient groups. PARTICIPANTS: 27 participants from 23 Australian patient groups that represented diverse levels of financial engagement with the pharmaceutical industry. Groups were focused on general health consumer issues or disease specific topics, and had regional or national jurisdictions. ANALYSIS: Analytic techniques were informed by grounded theory. Interview transcripts were coded into data driven categories. Findings were organised into new conceptual categories to describe and explain the data, and were supported by quotes. RESULTS: A range of attitudes towards pharmaceutical industry sponsorship were identified that are presented as four different types of relationship between patient groups and the pharmaceutical industry. The dominant relationship type was of a successful business partnership, and participants described close working relationships with industry personnel. These participants acknowledged a potential for adverse industry influence, but expressed confidence in existing strategies for avoiding industry influence. Other participants described unsatisfactory or undeveloped relationships, and some participants (all from general health consumer groups) presented their groups' missions as incompatible with the pharmaceutical industry because of fundamentally opposing interests. Participants reported that interactions between their patient group and pharmaceutical companies were more common when companies had new drugs of potential interest to group members. Patient groups that accepted industry funding engaged in exchanges of "assets" with companies. Groups received money, information, and advice in exchange for providing companies with marketing, relationship building opportunities with key opinion leaders, coordinated lobbying with companies about drug access and subsidy, assisting companies with clinical trial recruitment, and enhancing company credibility. CONCLUSIONS: An understanding of the range of views patient groups have about pharmaceutical company sponsorship will be useful for groups that seek to identify and manage any ethical concerns about these relationships. Patient groups that receive pharmaceutical industry money should anticipate they might be asked for specific assets in return. Selective industry funding of groups where active product marketing opportunities exist might skew the patient group sector's activity towards pharmaceutical industry interests and allow industry to exert proxy influence over advocacy and subsequent health policy.
引用
- Parker L, Fabbri A, Grundy Q, et al. "Asset exchange"-interactions between patient groups and pharmaceutical industry: Australian qualitative study. BMJ. 2019. PMID: 31831471. doi:10.1136/bmj.l6694
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。